When: Daily close above $70.30 + volume >10M + MACD histogram contracting

Then: Reach 1.25x full weight

When: Successful retest of $64-65 support followed by close back above 20-day VWMA

Then: Higher-probability second-entry setup

Hold existing positions; wait for new capital until the 50 SMA at 70.30 is reclaimed or the 200 SMA is successfully retested with rising volume.

• Three higher closes off a low does not confirm a basing structure; price remains below the 50 SMA at 70.30, below the Bollinger midline at 68.03, and barely above the 200 SMA
• The 9.3% gap-down on July 30th represents a confirmed breakdown that hasn't been addressed by three green candles
• Realistic reward-to-risk is closer to 1.5:1 (not 3:1) with first resistance at 68 (2.3%) and second resistance at 50 SMA 70.30 (5.7%), not the Bollinger upper band at 74.75
• Tail risk below the 200 SMA fails to 61.31 (Bollinger lower band), representing another 8% downside excluded from the aggressive thesis
• Low beta of 0.495 does not protect against tobacco-specific idiosyncratic risk like FDA menthol bans or dividend coverage questions that move MO 5-10% intraday regardless of market direction
• Options flow is directionally ambiguous and equally plausibly represents smart money hedging downside risk
• FDA menthol ban and nicotine cap regulations are live proceedings posing binary risk with no stop that survives a regulatory gap-down
• Free M&A optionality is speculation based on Polymarket probabilities at 42% with under $500 volume
• Negative book value structurally limits the buyer base, capping multiple expansion regardless of business quality
• Position sizing above benchmark into a broken structure with an untested 200 SMA is the opposite of conservative

→ vs aggressive: The 'textbook basing sequence' requires ignoring everything above the 10 EMA and the 50 SMA, which the entire market uses as the primary trend filter; three higher closes produce dead cat bounces within broken medium-term trends

→ vs aggressive: The reward-to-risk math presents the Bollinger upper band at 74.75 (12.4% upside) as the target, but first resistance at 68 (2.3%) and second resistance at 50 SMA 70.30 (5.7%) are the realistic outcomes; the tail risk scenario below 64 to 61.31 (8% additional downside) is excluded entirely

→ vs aggressive: Beta of 0.495 measures co-movement with the broad market, not tobacco-specific idiosyncratic risk; FDA announcements and credit rating questions produce 5-10% moves regardless of S&P direction

→ vs aggressive: Elevated options activity is directionally ambiguous by definition; framing it as bullish positioning is confirmation bias that ignores the equally plausible interpretation of downside hedging

→ vs aggressive: Regulatory risk (menthol ban, nicotine caps) is described as 'medium-to-long-term noise' but these are live proceedings that produce gap-downs that breach stops without warning

→ vs aggressive: The dividend opportunity cost argument is framing, not analysis; the cost of being wrong (8% capital loss plus lost dividend) far exceeds the cost of waiting three weeks (37 basis points)

→ vs aggressive: M&A optionality is based on Polymarket probabilities of 42% with under $500 traded volume, which is not actionable information

→ vs aggressive: Negative book value excludes MO from conservative mandates and institutional screens, structurally limiting the buyer base regardless of business quality

→ vs aggressive: Recommending 1.25x benchmark (or 1.5x) is the opposite of conservative positioning into a broken structure with an untested 200 SMA

BUY

• MO shows stabilization: price reclaimed 10 EMA and 20-day VWAP, RSI at 45.54, MACD approaching zero, closed above reported 200-day average after intraday test near $64.34
• MO remains below 50-day SMA around $70.30 and Bollinger midpoint around $68.03; MACD still below signal line; three higher closes establish possibility of base, not confirmed reversal
• From $66.50 entry, $68 target offers only 2.3% upside (not 5%+), less than one ATR ($1.73); $70.30 target offers ~5.7% upside or ~1.5x the $2.50 stop risk
• $74.75 Bollinger upper band produces ~3.3-to-1 reward-to-risk but is conditional best-case, 4.8 ATRs above entry, with first resistance at $68.03 not yet cleared
• $64 stop is ~1.45 ATR below entry but cannot protect against gap risk; MO's recent 9% earnings-related gap was several times current ATR; starter position must be small enough to tolerate 7-10% overnight gap
• FCF ~$9.04 billion vs ~$7 billion annual dividends gives ~1.3x coverage (adequate but not enormous cushion; if FCF fell to $7.5B, coverage would be ~1.07x)
• Dividend yield of 6.42% is only ~1.4 percentage points above 30-year Treasury yield above 5%, offering limited compensation premium for regulatory/business risk
• Beta of 0.495 means lower market sensitivity but does not capture company-specific risks (tobacco regulation, litigation, volume declines, dividend concerns)
• Prediction market 42% M&A probabilities across markets with less than $500 volume are not strong catalyst evidence
• Technical reports contain conflicting data: 200-day average varies between $64.39 and $65.74; treat levels as zones and confirm with live quote before entry

→ vs aggressive: Overstates reward-to-risk: $68 target is only 2.3% upside from $66.50 entry, not 5%+; 3-to-1 asymmetry at $74.75 is conditional best-case, not dependable base-case; $74.75 is 4.8 ATRs above entry and first resistance at $68.03 has not been cleared

→ vs aggressive: Wrong to use beta as reason to dismiss volatility; beta captures market sensitivity but not company-specific risks like tobacco regulation, litigation, volume declines, and event-driven earnings gaps

→ vs aggressive: Called three higher closes a 'textbook basing sequence' when it only establishes possibility of a base, not confirmed reversal; no durable close above medium-term trend level has occurred

→ vs aggressive: Treating weak, ambiguous signals (unusual options activity, low-volume prediction markets) as confirmation; options activity does not reveal direction

→ vs conservative: Too rigid demanding 50-day SMA reclaim before any action; waiting for close above $70.30 can mean paying ~5.7% more before same potential move to $74.75

→ vs conservative: Too dismissive of beta; lower market sensitivity is beneficial, just not a substitute for position sizing or event-risk management